Haycox, Alan <br/><br/>
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.  [electronic resource] 

 -  Drugs & aging  2009 
 - 791-801 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-1969 
<br/><br/><label>Standard No.: </label>10.2165/11316770-000000000-00000  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antiparkinson Agents--economics<br/>Benzothiazoles--economics<br/>Clinical Trials as Topic<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Dopamine Agonists--economics<br/>Female<br/>Health Care Costs<br/>Humans<br/>Indans--economics<br/>Insurance, Health, Reimbursement<br/>Male<br/>Markov Chains<br/>Middle Aged<br/>Models, Economic<br/>Monoamine Oxidase Inhibitors--economics<br/>Monte Carlo Method<br/>Parkinson Disease--drug therapy<br/>Pramipexole<br/>Probability<br/>Quality-Adjusted Life Years<br/>State Medicine<br/>Treatment Outcome<br/>United Kingdom